Cynata Therapeutics (ASX:CYP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cynata Therapeutics (ASX:CYP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Unmarketable Parcel Sale Facility
Notification of buy-back - CYP
Letter to Ineligible Shareholders-Entitlement Offer
Cynata launches $913,000 underwritten entitlement offer at 1 cent per share
Letter to Eligible Shareholders-Entitlement Offer
Cynata opens fully underwritten $913,000 entitlement offer
Replacement Target Market Determination
Cynata issues target market determination for new unquoted options
Replacement Prospectus
Cynata launches $913,000 underwritten entitlement offer with free options
Target Market Determination
Prospectus
Cynata launches A$913,000 underwritten entitlement offer amid funding and going-concern risks
Proposed issue of securities - CYP
Proposed issue of securities - CYP
Entitlement Offer & Unmarketable Parcel Sale Facility
Cynata launches fully underwritten $913,000 entitlement offer with free options
Termination of At-the-Market Subscription Deed
Cynata to terminate $7.5m ATM facility and seek cancellation of 7.2m security shares
Cynata Receives R&D TI Refund & Repays R&D TI Loan
Cynata receives $1.7m R&D refund and fully repays loan
R&D Tax Incentive Loan Facility Extension
Cynata extends $600,000 R&D loan maturity pending expected $1.7 million rebate
Date of AGM and Closing Date for Director Nominations
Appendix 4G
Corporate Governance Statement
Annual Report
Cynata reports failed clinical trials, major restructuring and material going concern uncertainty
Notification under Listing Rule 4.3D
Cynata increases FY2026 loss by $159,534 after CRO cost reconciliation
Notification of cessation of securities - CYP
Appendix 4E & Preliminary Final Report
Proposed issue of securities - CYP
June 2026 Quarterly Activity Report & Appendix 4C
Cynata Therapeutics reports mixed clinical trial results, implements major cost cuts, and secures R&D loan